• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Sylvant (siltuximab)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Sylvant (siltuximab)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Sylvant (siltuximab) is an anti-interleukin-6 (IL-6) chimeric monoclonal antibody that binds to human IL-6.1 IL-6 is a multifunctional cytokine produced by various cells such as T cells, B cells, monocytes, fibroblasts and endothelial cells. Dysregulated overproduction of IL-6 from activated B cells in affected lymph nodes has been implicated in the pathogenesis of, or mechanism causing, multicentric Castleman's disease.

    Sylvant is specifically indicated for the treatment of patients with multicentric Castleman’s disease who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.

    Sylvant is supplied as a solution for intravenous infusion. The recommended dose is 11 mg/kg is given over 1 hour as an intravenous infusion administered every three weeks until treatment failure.

    Clinical Results

    FDA Approval
    The FDA approval of Sylvant was based on a phase II, multinational, randomized, double blind, placebo controlled study. In this study 53 subjectswere randomized to Best Supportive Care (BSC) and Sylvant at a dose of 11 mg/kg every 3 weeks and 26 subjects were randomized to BSC and placebo. Treatment was continued until treatment failure (defined as disease progression based on increase in symptoms, radiologic progression or deterioration in performance status) or unacceptable toxicity. The major efficacy outcome of the study was durable tumor and symptomatic response, defined as tumor response assessed by independent review and complete resolution or stabilization of MCD symptoms. A durable response was defined as tumor and symptomatic response that persisted for a minimum of 18 weeks without treatment failure. The durable tumor and symptomatic response in the Sylvant arm was 34% compared to 0% in the placebo arm (p=0.0012).

    Side Effects

    Adverse effects associated with the use of Sylvant may include, but are not limited to, the following:

    • pruritus
    • increased weight
    • rash
    • hyperuricemia
    • upper respiratory tract infection

    Mechanism of Action

    Sylvant (siltuximab) binds human IL-6 and prevents the binding of IL-6 to both soluble and membrane-bound IL-6 receptors IL-6 has been shown to be involved in diverse normal physiologic processes such as induction of immunoglobulin secretion. Overproduction of IL-6 has been linked to systemic manifestations in patients with MCD.

    Additional Information

    For additional information regarding Sylvant or multicentric Castleman's disease, please visit the Sylvant web page.

    Approval Date: 2014-04-01
    Company Name: Janssen Biotech
    Back to Listings

    Upcoming Events

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • InputinLights-360x240.png

      Seeking Patient Input Early Helps Ensure Minority Participation in Trials

    • Oncology-360x240.png

      Global Oncology Trial Launches Drop Dramatically During Pandemic, Study Shows

    • Qualification-360x240.png

      Sites and Sponsors Streamlining Qualification Efforts with Technology, Process Revisions

    • New Algorithm Tested and Validated by CSDD Highly Predictive of Patient Burden

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing